Elastin Fragments in Blood Drive Aging by Triggering Chronic Inflammation

Aging research has long focused on cellular changes — senescence, telomere shortening, epigenetic drift — but the extracellular matrix (ECM) surrounding cells has received far less attention as a driver of systemic aging. This landmark study from Zhejiang University investigates whether ECM degradation products accumulating in circulation contribute causally to aging, and whether blocking their signaling could slow it.

The researchers measured serum levels of four major ECM-derived fragments — elastin (ELN), hyaluronic acid (HA), fibronectin (FN), and collagen (COL) — in 100 humans across age groups and in mice at five age points. All four fragment types showed significant positive correlation with age in both species. To test causality, mice received twice-weekly tail vein injections of each fragment type. Elastin-derived fragments produced the most potent aging effects: shortened lifespan, progressive weight gain with increased fat mass, reduced lean mass, diminished exercise capacity, elevated liver enzymes (AST/ALT), and systemic upregulation of inflammatory cytokines (IL-1, TNF, IL-6). Senescence markers (P16, P21, P53) were increased across multiple organs including liver, heart, kidney, spleen, muscle, and lung.

Mechanistically, the team identified the VGVAPG hexapeptide motif (E-motif), a conserved sequence within elastin, as the bioactive signal. This peptide activated monocytes and macrophages — but not T or B cells — through NEU1 (neuraminidase-1), a sialidase component of the elastin receptor complex on the cell surface. NEU1 activation triggered downstream NF-κB and MAPK inflammatory signaling, driving a chronic inflammatory state. Importantly, the authors validated these findings in a human cohort of 1,068 individuals, where circulating elastin fragment levels positively correlated with multiple aging biomarkers.

Therapeutically, treatment with a NEU1 inhibitor in naturally aged wild-type mice extended median lifespan by up to 17%, while also improving physical performance, reducing visceral fat, lowering systemic inflammation, and decreasing tissue senescence markers. These benefits were replicated in immune-humanized mice and in aged pigs, strengthening translational relevance across species.

This study establishes degraded ECM — particularly elastin fragments — as a previously underappreciated circulating driver of aging, operating through innate immune activation rather than direct cellular damage. It reframes the aging ECM as an active signaling compartment and positions the NEU1/elastin receptor axis as a tractable anti-aging drug target.